How much revenue does DexCom (DXCM) generate?

DexCom (DXCM) generated $4.82B in total revenue in TTM through Q1 2026, with a net profit margin of 19.3%, equivalent to roughly $930.40M in net income — what remains after every operating cost, interest payment, and income tax has been paid.

What is the gross profit margin of DexCom (DXCM)?

DexCom (DXCM) reported a gross profit margin of 61.8% in TTM through Q1 2026, equivalent to $2.98B in gross profit on $4.82B in revenue. Gross margin measures how much of each dollar of revenue remains after the direct cost of producing or delivering the product — a higher figure typically signals pricing power, scale, or a less capital-intensive business model.

What is the operating profit margin of DexCom (DXCM)?

DexCom (DXCM) reported an operating profit margin of 21.4% in TTM through Q1 2026, equivalent to $1.03B in operating income. Operating margin captures profitability after research & development, sales & marketing, and general & administrative expenses — but before interest, taxes, and one-off items — and is the cleanest single read on the underlying business's efficiency.

What is the net profit margin of DexCom (DXCM)?

DexCom (DXCM) reported a net profit margin of 19.3% in TTM through Q1 2026, equivalent to $930.40M in net income. Net margin is the bottom-line share of revenue that survives every expense — operating costs, interest, and income taxes — and is the figure that flows directly into earnings per share.

Is DexCom (DXCM) profitable?

Yes. DexCom (DXCM) reported $930.40M in net income for TTM through Q1 2026, with a net profit margin of 19.3%. The company earned more from its operations than it paid out in costs, interest, and income taxes, leaving positive earnings on the bottom line.

How much does DexCom (DXCM) invest in research and development?

DexCom (DXCM) invested $599.20M in research and development during TTM through Q1 2026, roughly 12.4% of total revenue. R&D spending funds the company's future product pipeline and is expensed in full on the income statement rather than capitalised, which makes the operating margin sensitive to how aggressively management chooses to reinvest in innovation.

How much does DexCom (DXCM) spend on capital expenditures?

DexCom (DXCM) spent $353.10M on capital expenditures (CapEx) during TTM through Q1 2026, roughly 7.3% of total revenue. CapEx represents long-lived investment in property, equipment, data centres, and other physical infrastructure, and is subtracted from operating cash flow to arrive at free cash flow.

How much free cash flow does DexCom (DXCM) generate?

DexCom (DXCM) generated $1.43B in free cash flow during TTM through Q1 2026, a free-cash-flow margin of 29.7%. Free cash flow is the cash left after capital expenditures and represents the discretionary pool the company can use to pay dividends, repurchase shares, repay debt, or fund acquisitions without raising external capital.

What is the effective tax rate of DexCom (DXCM)?

DexCom (DXCM) had an effective tax rate of 22.7% in TTM through Q1 2026. The effective rate is the actual share of pre-tax income paid as income taxes and can differ materially from the statutory rate due to foreign earnings mix, tax credits (such as R&D), share-based compensation deductions, and one-off discrete items.

Where does DexCom (DXCM) generate most of its revenue?

UNITED STATES is the largest geographic market for DexCom (DXCM), accounting for 54.7% of revenue in the most recent annual filing. The complete regional split — including international markets and any Rest-of-World rollup — is shown in the revenue-by-geography table on this page.

How DexCom Makes Money: 2026 Visual Revenue Map

DexCom (DXCM) Income Statement Flow — TTM through Q1 2026

Calculated from the four most recent reported quarters, ending March 31, 2026 (reported April 30, 2026).

DexCom (DXCM) Revenue by Geography — TTM through Q1 2026

Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported regions changed mid-year.

Revenue contribution by geographic region for DexCom (DXCM), TTM through Q1 2026
Region	Revenue (USD)	% of total
UNITED STATES	$1.69B	54.7%
Non-US	$1.40B	45.3%
Total	$3.09B	100%

UNITED STATES
Non-US
Total

Revenue Breakdown — TTM through Q1 2026

In TTM through Q1 2026, DexCom (DXCM) generated 54.7% of revenue from UNITED STATES, followed by Non-US (45.3%).

Frequently asked questions

Data & methodology

DexCom (DXCM) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Overview

DXCM Overview

Counters

Revenue Counter$152.77/s
Earnings Counter$29.50/s
Economic Scale> Liberia

Income Statement

How It Makes Money
Income Statement Waterfall
Profit Bridge

Cash Flow

Cash Flow Waterfall
Free Cash Flow Bridge

Capital Return

Buybacks2.22% TTM
Stock Split History1 split

Forecast & Valuation

Price Target Scenarios
Fair Value
What If Invested
Stock Seasonality
Daily Price Character49.5% win rate